Merck KGaA (FRA:MRK) has been given a €105.00 ($122.09) target price by Berenberg Bank in a research note issued on Friday, June 15th. The brokerage presently has a “buy” rating on the healthcare company’s stock. Berenberg Bank’s price objective suggests a potential upside of 28.30% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Goldman Sachs Group set a €100.00 ($116.28) price objective on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Friday, March 9th. UBS Group set a €115.00 ($133.72) price objective on shares of Merck KGaA and gave the stock a “buy” rating in a research report on Wednesday, April 4th. Kepler Capital Markets set a €106.00 ($123.26) price objective on shares of Merck KGaA and gave the stock a “buy” rating in a research report on Wednesday, June 13th. Nord/LB set a €84.00 ($97.67) price objective on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Monday, March 12th. Finally, DZ Bank restated a “buy” rating on shares of Merck KGaA in a research report on Monday, March 12th. Eleven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of €100.36 ($116.70).
Merck KGaA opened at €81.84 ($95.16) on Friday, MarketBeat reports. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.